# A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

> **NCT06514807** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AOP Orphan Pharmaceuticals AG** · enrollment: 117 (estimated)

## Conditions studied

- Essential Thrombocythaemia

## Interventions

- **DRUG:** Ropeginterferon alfa-2b (BESREMi®)

## Key facts

- **NCT ID:** NCT06514807
- **Lead sponsor:** AOP Orphan Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-04
- **Primary completion:** 2028-03-15
- **Final completion:** 2028-03-15
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06514807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06514807, "A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06514807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*